Lancet Oncology

文章摘录

• Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 tria Author: Gregorc, Vanesa; Majem, Margarita; Lo Russo, Giuseppe; Maio, Michele; Salvagni, Stephanie; Gutiérrez-Calderon, Vanesa; Gonzalez-Cao, Maria; Contreras, Sergio Sandiego; Koumarianou, Anna; Bearz, Alessandra; Bernabé-Caro, Reyes; Viteri, Santiago; de Sanmamed, Miguel Fernández; Zagouri, Flora; Bueno, Teresa Morán; Lazzari, Chiara; Martínez-Recio, Sergio; Giménez-Capitán, Ana; Zhang, Yue; Shan, Yue; Zhu, Huaqiang; Zhao, Congqiao; Shen, Haige; Wang, Yu; Rosell, Rafael Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 4, pp. 432-441. DOI: 10.1016/S1470-2045(25)00764-8
• Benmelstobart plus anlotinib versus pembrolizumab as first line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3tria Author: Zhong, Hua; Wang, Jing; Yang, Runxiang; Luo, Yongzhong; Zuo, Wei; Zhang, Wei; Xie, Chao; Li, Qingshan; Liu, Qiang; Xu, Xingxiang; Wang, Qiming; Yu, Yan; Chen, Yongxing; Yi, Tienan; Min, Xuhong; Shi, Jinsheng; Yang, Jian; Sun, Hongmei; Chen, Hualin; Shi, Huaqiu; Gao, Junzhen; Shi, Jianhua; Zhang, Bo; Chu, Tianqing; Li, Kai; Han, Baohui Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 4, pp. 419-431. DOI: 10.1016/S1470-2045(26)00049-5
• Fuzuloparib plus apatinib in BRCAmutated breast cancer: balancing efficacy and accessibility in regional Chin Author: Qiu, Ziran; Jin, Na Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e125-e125. DOI: 10.1016/S1470-2045(25)00752-1
• Fuzuloparib plus apatinib in BRCA- mutated breast cancer: balancing efficacy and accessibility in regional Chin Author: Liu, Jieqiong; Liu, Yaxin; Song, Erwei; Li, Huiping Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e126-e126. DOI:
• Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised double-blind, phase 3 stud Author: Dummer, Reinhard; Guo, Jun; Luke, Jason J.; Carlino, Matteo S.; Schadendorf, Dirk; Khattak, Muhammad A.; Hauschild, Axel; Ascierto, Paolo A.; Chen, Yu; Shin, Sang Joon; Rutkowski, Piotr; Luo, Zhiguo; Chen, Jing; Rivalland, Gareth; Coetzee, Corlia; Ribas, Antoni; Mujika, Karmele; Markel, Gal; Villarroel, Rodrigo U.; Dizdar, Omer; Caglevic, Christian; Grebennik, Dmitri; Donovan, Kevin; Krepler, Clemens; Long, Georgina, V Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. 327-339. DOI: 10.1016/S1470-2045(25)00709-0
• Standardising MET amplification testing: limitations of the GCN ≥6 criterion Repl Author: Wu, Yi-Long; Yao, Yu; Zhang, Pei-Long; Shi, He-Peng Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e128-e128. DOI:
• Standardising MET amplification testing: limitations of the GCN ≥6 criterio Author: Liu, Yuxin; Zhang, Dingdan; Tian, Shaodan Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e127-e127. DOI: 10.1016/S1470-2045(25)00758-2
• International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audit Author: Wong, Henry C. Y.; Choi, J. Isabelle; Marta, Gustavo Nader; Lee, Shing Fung; Chan, Adrian Wai; Santos, Monica D'alma Costa; Leung, Sheona; Wong, Edmond; Chan, Stephanie; Hircock, Caroline; Raman, Srinivas; Oldenburger, Eva; Simone Ii, Charles B.; Dearnaley, David; Maranzano, Ernesto; Chow, Edward; Rades, Dirk; Hoskin, Peter Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. e111-e122. DOI: 10.1016/S1470-2045(25)00602-3